Mostrar el registro sencillo del documento

dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.contributor.advisorMontoya Cárdenas, Rubén Danilo
dc.contributor.advisorSalazar Díaz, Luis Carlos
dc.contributor.authorHenao Gómez, Liliana
dc.date.accessioned2020-02-11T19:23:15Z
dc.date.available2020-02-11T19:23:15Z
dc.date.issued2020-01-07
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/75579
dc.description.abstractObjetivos: Describir las características clínicas, radiológicas e histopatológicas de los pacientes con hepatoblastoma en un hospital pediátrico durante el periodo 2008-2019. Métodos: Estudio retrospectivo de tipo descriptivo y corte transversal, con base en pacientes pediátricos con diagnóstico histológico de hepatoblastoma. Se recolectaron datos demográficos, clínicos, resultados de laboratorio e imagenológicos, los cuales se ordenaron usando el modelo internacional de clasificación del riesgo PRETEXT y se determinó la sobrevida al año de seguimiento. Resultados: Se realizó una revisión descriptiva en 27 pacientes con diagnóstico histopatológico de hepatoblastoma, 20 niños y 7 niñas, con un promedio de edad al diagnóstico de 28,6 meses. A 26 pacientes se les realizó ultrasonido (US) y se obtuvieron los datos de la historia clínica. A estos hallazgos se les aplicó la clasificación PRETEXT encontrando 15 pacientes con PRETEXT II, 10 pacientes con PRETEXT III y 1 paciente con PRETEXT IV. Se practicaron 19 tomografías computarizadas (TC) y 8 resonancias magnéticas (RM) y se estadificaron nuevamente obteniendo 1 paciente con PRETEXT I, 11 pacientes con PRETEXT II, 9 pacientes con PRETEXT III y 5 pacientes con PRETEXT IV. No se demostraron diferencias significativas en los grupos PRETEXT II y III entre las técnicas de US, TC y RM. No obstante, la RM demostró mayor especificidad en los pacientes PRETEXT IV. Respecto de los factores de anotación, los más relevantes fueron el compromiso de la venas suprahepáticas o de la VCI (V) y el de la vena porta o (P), que ocurrieron especialmente en los pacientes con PRETEXT IV y en 4 pacientes PRETEXT III. El compromiso del lóbulo caudado (C) fue del 15% en cuatro pacientes y las metástasis (M) en 10 pacientes que correspondieron al 34%. La sobrevida estimada al año fue de 59.9.%. Palabras clave (DeCS): hepatoblastoma, PRETEXT, ultrasonido (US), tomografía computarizada (TC), resonancia magnética (RM), factores de anotación.
dc.description.abstractObjectives: To describe the clinical, radiological and histopathological characteristics of patients with hepatoblastoma in a pediatric hospital between 2008-2019. Methods: A retrospective cross-sectional descriptive study, based on pediatric patients with a histological diagnosis of hepatoblastoma. Demographic and clinical data were collected, as well as laboratory and image results, which were ordered using the international PRETEXT risk classification model; survival was established after a one-year follow-up. Results: A descriptive review was conducted for 27 patients with histopathological diagnoses of hepatoblastoma –20 boys and 7 girls– with an average age of 28.6 months at the time of diagnosis. Twenty-six of these patients underwent ultrasounds and their medical history was obtained. The PRETEXT classification was applied to this information, which resulted in 15 patients with PRETEXT II, 10 patients with PRETEXT III and 1 patient with PRETEXT IV. Nineteen CTs and 8 MRIs were taken and staged according to PRETEXT in 1 patient with PRETEXT I, 11 patients with PRETEXT II, 9 patients with PRETEXT III and 5 patients with PRETEXT IV. No significant differences were found in PRETEXT II and PRETEXT II between USs, and the CTs and MRIs. However, the MRI showed a higher specifity in PRETEXT IV patients. Annotation factors were also used to demonstrate the involvement of V (suprahepatic or IVC), P (portal vein), E (extrahepatic extension), F (multifocal tumor), R (ruptured tumor), C (caudate compromise), N (lymph node compromise), M (distant metastasis). Regarding the annotation factors, the most relevant were the commitment of the suprahepatic veins or of the IVC (V) and that of the portal vein or (P), which occurred especially in patients with PRETEXT IV and in 4 PRETEXT III patients. The compromise of the caudate lobe (C) was 15% in four patients and metastases (M) in 10 patients corresponding to 34%. The estimated survival per year was 59.9%. Keywords (DeCS): Hepatoblastoma, PRETEXT, ultrasound (US), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), annotation factors.
dc.format.extent63
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddcMedicina y salud
dc.titleCaracterización radiológica, clínica y patológica del hepatoblastoma en un hospital pediátrico de referencia oncológica
dc.typeDocumento de trabajo
dc.rights.spaAcceso abierto
dc.description.additionalEspecialista en Radiología Pediátrica
dc.type.driverinfo:eu-repo/semantics/other
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1. Tulla M, Berthold F, Graf N, Rutkowski S, Von Schweinitz D, Spix C, et al. Incidence, trends, and survival of children with embryonal tumors. Pediatrics. 2015;136(3):e623–32. 2. Allan BJ, Parikh PP, Diaz S, Perez EA, Neville HL, Sola JE. Predictors of survival and incidence of hepatoblastoma in the paediatric population. Hpb. 2013;15(10):741–6. doi: 10.1111/hpb.12112 3. Chung EM, Lattin GE, Cube R, Lewis RB, Marichal-Hernández C, Shawhan R, et al. From the Archives of the AFIP: Pediatric Liver Masses: Radiologic-Pathologic Correlation Part 2. Malignant Tumors. RadioGraphics. 2011 Mar;31(2):483–507. 4. Uribe CJ, Amado AM, Ramírez G, Alarcón IC. Cáncer infantil en el área metropolitana de Bucaramanga, Colombia, 2003-2007. MedUNAB. 2011 ago-nov;14(2): 86-93. Disponible en: https://revistas.unab.edu.co/index.php/medunab/article/view/1383. 5. Caicedo LA, Sabogal A, Serrano O, Villegas JI, Botero V, Agudelo MT, et al. Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center. Transplant direct. 2017;3(6):e165. 6. Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, et al. Risk-stratified staging in paediatric hepatoblastoma: A unified analysis from the Children’s Hepatic Tumors International Collaboration. Lancet Oncol. 2017;18(1):122–31. 7. Schnater, J.M. The way forward in hepatoblastoma: A study of epidemiology, gene expresión patterns, and the development of a tumor model [PhD tesis en Internet]. Amsterdam (Holanda): University of Amsterdam; 2006 [citado 2019 oct 27]. Disponible en: https://hdl.handle.net/11245/1.258938 8. Huang LC, Ho M, Chang WC, Chen HY, Hung YC, Chiu TH. Prenatal diagnosis of fetal hepatoblastoma with a good neonatal outcome: Case report and narrative literature review. Pediatr Hematol Oncol. 2011;28(2):150–4. 9. Spector LG, Birch J. The Epidemiology of Hepatoblastoma. Pediatr Blood Cancer. 2013;60(2, poster 619):S41. 10. Misick OS. A case of teratoma hepatis. J Pathol Bacteriol. 1898;5(1):128–36. 11. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer.1967 marzo;(20)3:396–422. https://doi.org/10.1002/1097- 0142(1967)20:3<396::AID-CNCR2820200308>3.0.CO;2-O 12. Monsalve J, Kapur J, Malkin D, Babyn P. Imaging of cancer predisposition syndromes in children. Pediatr Radiol. 2018;48(9):1364–75. 13. Mussa A, Russo S, Larizza L, Riccio A, Ferrero GB. (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome: A paradigm for genomic medicine. Clin Genet. 2016;89(4):403–15. 14. Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16(3):195–203. 15. Isaacs H. Fetal and neonatal hepatic tumors. J Pediatr Surg. 2007;42(11):1797–803. 16. Spector LG, Puumala SE, Carozza SE, Chow EJ, Fox EE, Horel S, et al. Cancer risk among children with very low birth weights. Pediatrics. 2009;124(1):96–104. 17. Trobaugh-Lotrario AD, López-Terrada D, Li P, Feusner JH. Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening. Pediatr Blood Cancer. 2018;65(8):1–7. 18. Yang A, Sisson R, Gupta A, Tiao G, Geller JI. Germline APC mutations in hepatoblastoma. Pediatr Blood Cancer. 2018;65(4). 19. Giardiello FM, Petersen GM, Brensinger JD, Luce MC, Cayouette MC, Bacon J, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut. 1996;39(6):867–9. 20. Rengifo-Cam W, Jasperson KW, Burt RW, Samadder NJ. Familial adenomatous polyposis. En: Intestinal Polyposis Syndromes: Diagnosis and Management. Nueva York: Springer International Publishing; 2016. p. 173-195. https://doi.org/10.1007/978-3-319-28103- 2_11 21. Das CJ, Dhingra S, Gupta AK, Iyer V, Agarwala S. Imaging of paediatric liver tumours with pathological correlation. Clin Radiol. 2009 Oct;64(10):1015–25. 22. Turcotte L, Georgieff M, Ross J, Feusner J, Tomlinson G, Malogolowkin M, et al. Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases: A Report From the Children’s Oncology Group. Pediatr Blood Cancer. 2014;23(1):1–7. 23. Feusner J, Plaschkes J. Hepatoblastoma and low birth weight: A trend or chance observation? Med Pediatr Oncol. 2002;39(5):508–9. 24. Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment. Transl Pediatr. 2014;3(4):293–9. 25. Tanimura M, Matsui I, Abe J, Ikeda H, Kobayashi N, Ohira M, et al. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res. 1998;58(14):3032–5. 26. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956;8(2):174. Doi: 10.3109/00365515609049266 27. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963 abril;1:174– 80. Doi: 10.1097/00007890-196301020-00004. 28. Abelev G, Assecritova I, Kraevsky N, Perova S, Perevodchikova N. Milestones in liver disease. J Hepatol. 2002;37:172–5. 29. Trichopoulos D, Sizaret P, Tabor E, Gerety RJ, Martel N, Munoz N, et al. Alphafetoprotein levels of liver cancer patients and controls in a European population. Cancer. 1980;46(4):736–40. 30. Masopust J, Kithier K, Rádl J, Koutecký J, Kotál L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic diseases. Int J Cancer. 1968 mayo 15;3(3):364–73. 31. Linson EA, Hanauer SB. More than a tumor marker⋯A potential role for alpha-feto protein in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(7):1271–6. 32. Gitlin D, Perricelli A, Gitlin GM. Synthesis of A-Fetoprotein by Liver, Yolk Sac, and Gastrointestinal Tract of the Human Conceptus. Cancer Res. 1972;32(5):979–82. 33. Maldonado Mercado MG, Pereyra Morales MA, Zenteno Galindo EA. Estructura y función de la alfa-fetoproteína. Rev Fac Med UNAM. 2015;58(4):5–13. Disponible: https://www.medigraphic.com/pdfs/facmed/un-2015/un154b.pdf [consulta: 2019-10- 30] 34. Taketa K. α-fetoprotein: Reevaluation in hepatology. Hepatology. 1990;12(6):1420–32. 35. Ng K, Mogul DB. Pediatric Liver Tumors. Clin Liver Dis. 2018;22(4):753–72. 36. Men S, Hekimoǧlu B, Tüzün M, Arda IS, Pinar A. Unusual US and CT findings in hepatoblastoma: A case report. Pediatr Radiol. 1995;25(7):507–8. 37. López-Terrada D, Alaggio R, De Dávila MT, Czauderna P, Hiyama E, Katzenstein H, et al. Towards an international pediatric liver tumor consensus classification: Proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27(3):472–91. 38. Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Maibach R, et al. The Children’s Hepatic Tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;92–101. 39 Men S, Hekimoglu B, Tuzun M, Arda IS, Pinar A. Unusual US and CT findings in hepatoblastoma: a case report. Pediatr Radiol. 1995;25(7):507–8. 40. McCarville, M B, Roebuck DJ. Diagnosis and Staging of Hepatoblastoma: Imaging Aspects. Pediatr Blood Cancer. 2013;60(2, poster 619):S41. 41. Kao SC, McCarville MB. Imaging recommendations for malignant liver neoplasms in children. Pediatr Blood Cancer. 2006;46(1):2–7. 42. McHugh K, Disini L. Commentary: For the children-s sake, avoid non-contrast CT. Cancer Imaging. 2011 marzo;11(1):16–8. Doi 10.1102/1470-7330.2011.0003. 43. Shelmerdine SC, Roebuck DJ, Towbin AJ, McHugh K. MRI of paediatric liver tumours: How we review and report. Cancer Imaging. 2016;16(1):1–10. 44. Sirignano M, Dillman JR, Weiss BD, Quinn CT, Zhang B, Su W, et al. Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors. Pediatr Radiol. 2018;48(3):325–32. 45. Meeus EM, Zarinabad N, Manias KA, Novak J, Rose HEL, Dehghani H, et al. Diffusionweighted MRI and intravoxel incoherent motion model for diagnosis of pediatric solid abdominal tumors. J Magn Reson Imaging. 2018;47(6):1475–86. 46. Shamir SB, Kurian J, Kogan-Liberman D, Taragin BH. Hepatic imaging in neonates and young infants: State of the art. Radiology. 2017;285(3):763–77. 47. Masand PM. Magnetic resonance imaging features of common focal liver lesions in children. Pediatr Radiol. 2018;48(9):1234–44. 48. Chung EM, Cube R, Lewis RB, Conran RM. From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation Part 1. Benign Tumors. Radiographics. 2010 mayo [citado 2019-10-30];30(3):801–26. Disponible en: https://pubs.rsna.org/doi/10.1148/rg.303095173 49. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville Goyet J, Gauthier F, et al. 2005 PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123–32. 50. Couinaud C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver [artículo en francés]. Presse Med. 1954 mayo 5;62(33):709-12. 51. Cistaro A, Treglia G, Pagano M, Fania P, Bova V, Basso ME, et al. A comparison between FFDG PET/CT imaging and biological and radiological findings in restaging of hepatoblastoma patients. Biomed Res Int. 2013;2013. 52. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol. 2000;1(2):94–100. 53. Aronson DC, Czauderna P, Maibach R, Perilongo G, Morland B. The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg. 2014 octubre [citado 2019-10-30];19(4):201–7. Doi: 10.4103/0971- 9261.142001. Disponible en: http://www.jiaps.com/text.asp?2014/19/4/201/142001 54. Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018 abril [citado 2019-10-30];48(4):536–54. Doi: 10.1007/s00247-018-4078-z. Disponible en: https://link.springer.com/article/10.1007%2Fs00247-018-4078-z 55. Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, et al. Pretreatment prognostic factors for children with hepatoblastoma - Results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer. 2000;36(11):1418– 25. 56. Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584–90. 57. Baheti AD, Chapman T, Rudzinski E, Albert CM, Stanescu AL. Diagnosis, histopathologic correlation and management of hepatoblastoma: What the radiologist needs to know. Clin Imaging. 2018 [citado 2019-10-30];52:273–9. Doi: 10.1016/j.clinimag.2018.08.009. Disponible en: https://www.clinicalimaging.org/article/S0899-7071(18)30230-4/fulltext 58. Manterola C, Sol M del, Ottone N, Otzen T. Radiological and Surgical Anatomy of the Liver and Fundamentals of the Various Options Liver Resections. Int J Morphol. 2017;35(4):1525–40. 59. Meyers RL, Tiao G, De Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art. Curr Opin Pediatr. 2014;26(1):29-36. 60. Yadav SS, Lawande MA, Patkar DA, Pungavkar SP. Rare case of hemorrhagic brain metastasis from hepatoblastoma. J Pediatr Neurosci 2012;7:73-4.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalHepatoblastoma
dc.subject.proposalHepatoblastoma
dc.subject.proposalPRETEXT
dc.subject.proposalUltrasonido (US)
dc.subject.proposalUltrasound (US)
dc.subject.proposalPRETEXT
dc.subject.proposalTomografía computarizada (TC)
dc.subject.proposalComputed Tomography (CT)
dc.subject.proposalMagnetic Resonance Imaging (MRI)
dc.subject.proposalResonancia magnética (RM)
dc.subject.proposalFactores de anotación
dc.subject.proposalAnnotation factors
dc.type.coarhttp://purl.org/coar/resource_type/c_1843
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial-SinDerivadas 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito